OSLO Dec 19 It's unlikely that anyone will make
a competing offer for Norwegian cancer drug firm Algeta
after Germany's Bayer raised its bid by
7.7 percent on Thursday, Algeta shareholder Alfred Berg Capital
Management told Reuters.
The asset manager holds 0.4 percent of the company's shares.
"It looks like the board has done its best to get an
increased bid. So this won't be the hardest decision we've had
to make," fund manager Leif Eriksroed said.
"The offer is in the ball park. It's recommended by the
board and there are no other bids," he added.
Alfred Berg will make a formal decision on whether to sell
its stake at the current offer price at a later stage.
(Reporting by Joachim Dagenborg, writing by Terje Solsvik,
editing by Gwladys Fouche)